Antibodies recognising M13 filamentous phage coat proteins are instrumental in the selection and detection of phages expressing specific antibody fragments or peptide sequences at their surface. The monoclonal antibodies manufactured and supplied by Exalpha react with either the pIII (g3p) or pVIII (g8p) proteins of M13 filamentous bacteriophage. All antibodies are available in a purified format. The antibodies are fully validated and are suitable for a wide range of techniques including:
For more information, click here for our M13 Bacteriophage information page.
Two more of our excellent products have been published by PubMed:
Influenza A, H1N1 New Caledonia 20/99, Hemagglutinin, Recombinant (Full Length)
≥ 90% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Endotoxin: ≤ 0.1ng/ug (IEU/ug).
Influenza virus is a single-stranded RNA virus, segmented, 70nm in diameter and enveloped. Strains are described by geographic origin, strain number, year of isolation and hemagglutination (H) and neuraminidase (N) antigens.
Recombinant full-length H1N1 A/New Caledonia/20/99 (MW 72kD) is glycosylated with N-linked sugars and produced using baculovirus vectors in insect cells. The insect cells were infected with A9440.1a, recombinant baculovirus expressing recombinant H1N1 A/New Caledonia/20/99. H1N1 New Caledonia shows 90% similarity to the A/PR/8/34 amino acid sequence.
Recombinant full-length H1N1 A/New Caledonia/20/99 (MW 7.5kD) is glycosylated with N-linked sugars and produced using baculovirus vectors in insect cells. The insect cells were infected with A9440.1a, recombinant baculovirus expressing recombinant H1N1 A/New Caledonia/20/99. H1N1 New Caledonia shows 90% similarity to the A/PR/8/34 amino acid sequence.
Supplied as a sterile solution in 10mM sodium phosphate, pH 7.2, 150mM sodium chloride.
May be stored at 4°C for short-term only. For long-term storage, add 0.1% HSA or BSA, store at -20°C. Aliquots are stable for at least 6 months at -20°C.
Target Molecular Weight
1. Wrammert, J., et al. “Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.” J. of Exp. Med. (2011), 208, 181-193.